Q-omics provides the consensus-scored RPSAP25 profile across patient tissues and cancer cell-line models. RPSAP25 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPSAP25 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, RPSAP25 RNA expression shows 5,645 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, THCA, and STAD as cancer lineages where RPSAP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP25 survival associations across molecular data types. RPSAP25 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP25 RNA expression–survival associations across cancer types. High RPSAP25 expression shows unfavorable associations in MESO, ESCA, LUSC, PAAD and THYM, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .020). Together, the overview and detailed table identify MESO as the clearest survival context for RPSAP25 RNA expression.
This table summarizes RPSAP25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP25 shows lower tumor expression in THCA and KICH and higher tumor expression in BRCA and KIRC. The THCA box plot shows higher RPSAP25 RNA expression in normal versus tumor tissue (log2 FC = −0.020, t-test p = .007).
This table shows molecular features associated with RPSAP25 in patient tissues and cancer cell lines. In patient samples, RPSAP25 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
